Advanced search
Publication Cover
Expert Review of Cardiovascular Therapy Volume 10, 2012 - Issue 10
Submit an article Journal homepage
159
Views
3
CrossRef citations to date
0
Altmetric
Review

Update on guidelines for management of hypercholesterolemia

Gurdeep S Mannu Norfolk and Norwich University Hospital, Norfolk, UK. [email protected]; Norfolk and Norwich University Hospital, Norfolk, UK. [email protected]
,
M Justin S Zaman James Paget University Hospital, Great Yarmouth, Norfolk, UK; James Paget University Hospital, Great Yarmouth, Norfolk, UK
,
Abhaya Gupta Department of Medicine, West Wales Hospital, Carmarthen, SA31 2AF, Wales, UK; Department of Medicine, West Wales Hospital, Carmarthen, SA31 2AF, Wales, UK
,
Habib U Rehman University of Saskatchewan, SK, S7N 5A2, Canada; University of Saskatchewan, SK, S7N 5A2, Canada
&
Phyo K Myint Norwich Medical School, Faculty of Medicine and Health Sciences, University of East Anglia, Norwich Research Park, Norwich, UK; Norwich Medical School, Faculty of Medicine and Health Sciences, University of East Anglia, Norwich Research Park, Norwich, UK
Pages 1239-1249 | Published online: 10 Jan 2014

References

  • Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet 353(9147), 89–92 (1999).
  • Duvall WL, Vorchheimer DA. Multi-bed vascular disease and atherothrombosis: scope of the problem. J. Thromb. Thrombolysis 17(1), 51–61 (2004).
  • Reddy K. Global perspective on cardiovascular disease. In: Evidence-Based Cardiology. Yusuf S, Cairns JA, Camm AJ, Fallen EL, Gersh BJ (Eds). Wiley-Blackwell, London, UK (2009).
  • Verschuren WM, Jacobs DR, Bloemberg BP et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. JAMA 274(2), 131–136 (1995).
  • LaRosa JC, Hunninghake D, Bush D et al. The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholesterol Issues, American Heart Association. Circulation 81(5), 1721–1733 (1990).
  • Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 308(6925), 367–372 (1994).
  • The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 251(3), 351–364 (1984).
  • Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 256(20), 2823–2828 (1986).
  • NCEP. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment Panel III). JAMA 285(19), 2486–2497 (2001).
  • Chen Z, Peto R, Collins R, MacMahon S, Lu J, Li W. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ 303(6797), 276–282 (1991).
  • Wilson PW, Anderson KM, Castelli WP. Twelve-year incidence of coronary heart disease in middle-aged adults during the era of hypertensive therapy: the Framingham offspring study. Am. J. Med. 90(1), 11–16 (1991).
  • Assmann G, Cullen P, Schulte H. The Münster Heart Study (PROCAM). Results of follow-up at 8 years. Eur. Heart J. 19(Suppl. A), A2–A11 (1998).
  • Manninen V, Elo MO, Frick MH et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 260(5), 641–651 (1988).
  • Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279(20), 1615–1622 (1998).
  • Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 333(20), 1301–1307 (1995).
  • Sever PS, Dahlöf B, Poulter NR et al.; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo–Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361(9364), 1149–1158 (2003).
  • Colhoun HM, Betteridge DJ, Durrington PN et al.; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in Type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364(9435), 685–696 (2004).
  • Baigent C, Keech A, Kearney PM et al.; Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493), 1267–1278 (2005).
  • Kearney PM, Blackwell L, Collins R et al.; Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371(9607), 117–125 (2008).
  • 4S-Study. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344(8934), 1383–1389 (1994).
  • Lipid-Study. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N. Engl. J. Med. 339(19), 1349–1357 (1998).
  • Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360(9326), 7–22 (2002).
  • LaRosa JC, Grundy SM, Waters DD et al.; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 352(14), 1425–1435 (2005).
  • O’Keefe JH Jr, Cordain L, Harris WH, Moe RM, Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J. Am. Coll. Cardiol. 43(11), 2142–2146 (2004).
  • Ray KK, Cannon CP, McCabe CH et al.; PROVE IT-TIMI 22 Investigators. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J. Am. Coll. Cardiol. 46(8), 1405–1410 (2005).
  • PROVE-IT TIMI 22 Trial. Report of the national cholesterol education program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. The expert panel. Arch. Intern. Med. 148(1), 36–69 (1988).
  • ATP II. National Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment Panel II). Circulation 89(3), 1333–1445 (1994).
  • National Service Framework. Chapter 2. Preventing coronary heart disease in high risk patients. Modern Standards and Service Models (2000).
  • Graham I, Atar D, Borch-Johnsen K et al.; European Society of Cardiology (ESC); European Association for Cardiovascular Prevention and Rehabilitation (EACPR); Council on Cardiovascular Nursing; European Association for Study of Diabetes (EASD); International Diabetes Federation Europe (IDF-Europe); European Stroke Initiative (EUSI); Society of Behavioural Medicine (ISBM); European Society of Hypertension (ESH); WONCA Europe (European Society of General Practice/Family Medicine); European Heart Network (EHN); European Atherosclerosis Society (EAS). European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur. J. Cardiovasc. Prev. Rehabil. 14(Suppl. 2), S1–S113 (2007).
  • Reiner Z, Catapano AL, De Backer G et al.; European Association for Cardiovascular Prevention & Rehabilitation; ESC Committee for Practice Guidelines (CPG) 2008–2010 and 2010–2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur. Heart J. 32(14), 1769–1818 (2011).
  • Doh. Department of Health. The New GMS Contract. Investing in general practice. Annex A, London, UK, 56–71 (2003).
  • Williams B, Poulter NR, Brown MJ et al. BHS guidelines working party, for the British Hypertension Society. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 328(7440), 634–640 (2004).
  • Catapano AL, Reiner Z, De Backer G et al.; European Society of Cardiology (ESC); European Atherosclerosis Society (EAS). ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 217(1), 3–46 (2011).
  • Wood D. International task force for prevention of coronary heart disease/International Atherosclerosis Society. Coronary Heart Disease. Reducing the risk. Nutr. Metab. Cardiovasc. Dis. 8, 205–271 (1998).
  • JBS-2. JBS 2: Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart 91(Suppl. 5), v1–v52 (2005).
  • British Cardiac Society BHA, British Hypertension Society, British Diabetic Association. Joint British recommendations on detection, evaluation and treatment of high blood cholesterol in adults. Heart 80(Suppl. 2), S1–S5.29 (1998).
  • Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 297(6), 611–619 (2007).
  • NICE. Type 2 diabetes: the management of Type 2 diabetes. NICE Guidelines (2009).
  • NICE. Lipid modification Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. NICE Guidelines (2008).
  • NICE. Post Myocardial Infarction Secondary prevention in primary and secondary care for patients following a myocardial infarction full guideline – final version. NICE Guidelines (2007).
  • NICE. Secondary prevention of coronary heart disease. NICE Indicator Guidance for QOF (2010).
  • NICE. Quality and outcomes framework (QOF) indicator guidance. Indicator area: primary prevention of cardiovascular disease. NICE Indicator Guidance for QOF (2011).
  • SIGN. Risk estimation and the prevention of cardiovascular disease. A national clinical guideline. Scottish Intercollegiate Guidelines Network (2007).
  • D’Agostino RB Sr, Grundy S, Sullivan LM, Wilson P; CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 286(2), 180–187 (2001).
  • Brindle P, Emberson J, Lampe F et al. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ 327(7426), 1267 (2003).
  • Bastuji-Garin S, Deverly A, Moyse D et al.; Intervention as a Goal in Hypertension Treatment Study Group. The Framingham prediction rule is not valid in a European population of treated hypertensive patients. J. Hypertens. 20(10), 1973–1980 (2002).
  • Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Brindle P. Performance of the QRISK cardiovascular risk prediction algorithm in an independent UK sample of patients from general practice: a validation study. Heart 94(1), 34–39 (2008).
  • Blumenthal RS, Michos ED, Nasir K. Further improvements in CHD risk prediction for women. JAMA 297(6), 641–643 (2007).
  • D’Agostino RB Sr, Vasan RS, Pencina MJ et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 117(6), 743–753 (2008).
  • Wilson PW. Progressing from risk factors to omics. Circ. Cardiovasc. Genet. 1(2), 141–146 (2008).
  • Sniderman AD, Furberg CD. Age as a modifiable risk factor for cardiovascular disease. Lancet 371(9623), 1547–1549 (2008).
  • Pencina MJ, D’Agostino RB Sr, Larson MG, Massaro JM, Vasan RS. Predicting the 30-year risk of cardiovascular disease: the Framingham Heart Study. Circulation 119(24), 3078–3084 (2009).
  • Lloyd-Jones DM, Leip EP, Larson MG et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 113(6), 791–798 (2006).
  • Genest J, McPherson R, Frohlich J et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations. Can. J. Cardiol. 25(10), 567–579 (2009).
  • National Institute for Health and Clinical Excellence. Lipid modification (CG67). Clinical Guidelines (2008).
  • Reynolds TM, Twomey P, Wierzbicki AS. Accuracy of cardiovascular risk estimation for primary prevention in patients without diabetes. J. Cardiovasc. Risk 9(4), 183–190 (2002).
  • NICE. National Collaborating Centre for Chronic Conditions. Type 2 diabetes: national clinical guideline for management in primary and secondary care (update). National Collaborating Centre for Chronic Conditions. Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (update) (2008).
  • Snow V, Aronson MD, Hornbake ER, Mottur-Pilson C, Weiss KB; Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Lipid control in the management of Type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann. Intern. Med. 140(8), 644–649 (2004).
  • College of Physicians A. Summaries for patients. Control of lipids in patients with Type 2 diabetes: recommendations from the American College of Physicians. Ann. Intern. Med. 140(8), I85 (2004).
  • Minhas R. Eminence-based guidelines: a quality assessment of the second Joint British Societies’ guidelines on the prevention of cardiovascular disease. Int. J. Clin. Pract. 61(7), 1137–1144 (2007).
  • Unwin N, Thomson R, O’Byrne AM, Laker M, Armstrong H. Implications of applying widely accepted cholesterol screening and management guidelines to a British adult population: cross sectional study of cardiovascular disease and risk factors. BMJ 317(7166), 1125–1130 (1998).
  • Resnick HE, Jones K, Ruotolo G et al. Strong Heart Study. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic American indians: the Strong Heart Study. Diabetes Care 26(3), 861–867 (2003).
  • ALLHAT-LLT. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 288(23), 2998–3007 (2002).
  • American College of Physicians. Guidelines for using serum cholesterol, high-density lipoprotein cholesterol, and triglyceride levels as screening tests for preventing coronary heart disease in adults. American College of Physicians. Part 1. Ann. Intern. Med. 124(5), 515–517 (1996).
  • Lazar LD, Pletcher MJ, Coxson PG, Bibbins-Domingo K, Goldman L. Cost–effectiveness of statin therapy for primary prevention in a low-cost statin era. Circulation 124(2), 146–153 (2011).
  • Baigent C, Blackwell L, Emberson J et al. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376(9753), 1670–1681 (2010).
  • Mills EJ, O’Regan C, Eyawo O et al. Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of >40 000 patients. Eur. Heart J. 32(11), 1409–1415 (2011).
  • Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. 335(14), 1001–1009 (1996).
  • Shepherd J, Blauw GJ, Murphy MB et al.; PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360(9346), 1623–1630 (2002).
  • Rose G. The Strategy of Preventive Medicine. Oxford Medical Publications, Oxford, London, UK (1994).
  • Mora S, Szklo M, Otvos JD et al. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 192(1), 211–217 (2007).
  • Packard CJ. Small dense low-density lipoprotein and its role as an independent predictor of cardiovascular disease. Curr. Opin. Lipidol. 17(4), 412–417 (2006).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.